Who We Are
Wellmarker Bio Co., Ltd.(WMBIO) Develops Anticancer Drugs Based on Predictive Biomarkers for Unmet Medical Needs
Wellmarker Bio is a spin-off company from Seoul Asan Medical Center (AMC), which is the largest and most renowned hospital in the Republic of Korea. We specialize in developing predictive biomarkers and first-in-class drugs through profound research know-hows and clinical information from AMC. We strive to bring a better outcome to patients and contribute to the healthy life of a mankind through ‘New Drug Development Research Institute’ that is comprised of bio-research center, medicinal chemistry research center, cmc center and clinical development center.
Areas of Expertise
We are developing predictive biomarkers and anticancer drugs for solid tumors by utilizing in-house research facilities and clinical information from AMC.
On many occasions, “new drug development” can be said to be a “comprehensive art.” To perform this “comprehensive art”, it requires an amazing storyline, stage setting, and above all, a great actor. In the same way, WMBIO continues to make ceaseless effort on developing new drugs by working together with global partners. We will continue to strive in contributing to the healthy life of mankind.
Company History
12 Company Founded
04 R&D Center Established
05 Pipeline WM-S1(Small Molecule, Colon Cancer)
Has Been Selected by KDDF
* KDDF: Korea Drug Development Fund
07 Acquired the Venture Business Certification
10 Research Collaboration Agreement with Y-Biologics
02 Pipeline WM-A1(Therapeutic Antibody, Lung Cancer) Has Been Selected by KDDF
10 Completed Series A($28million)
02 MOU Signed with KIRAMS
(Korea Institute for Radiological and Medical Sciences)
03 MOU Signed with Ukrainian National Medical Institutions (VNMU/PRCO)
03 Pipeline WM-S1 Has Been Selected as
a KDDF Follow-up Project
06 MOU Signed with Cytogen for
Companion Diagnostics
07 Signed Technology Transfer Contract with KIRAMS(L/I)
07 Completed Series B($18million)
10 MOU Signed with Azothbio
10 Received the Grand Prize at the
‘2019 5th Korean Good Company Awards’ in Bio Sector
03Research Collaboration Agreement with AzothBio on AI-based Anticancer Drug Development
05Branch Research Center(CMC Center) Established
05‘Startup Scale-Up Package’ Program Selected by MSS
* MSS: Ministry of SMEs and Startups
10Received the Grand Prize at the ‘2020 6thKorean Good Company Awards’ in Bio Sector for 2 Consecutive Years
CI Guideline
The Company Logo of WMBIO Embodies
the Corporate Value of Pursing a Happy Future and a Healthy Life of Mankind
A balanced, solid and stable hexagonal frame represents the best global biotechnology company with experienced researchers and technology. It implicitly visualizes fruit and lantern that lights up the future through innovation, determination, and strong leadership in bio industry.
Organizational Structure
Collaborations
Wellmarker Bio is Committed to Developing New Drugs through
Continuous Cooperation with Global Partners
